[{"symbol": "EXAS", "price": 102.43, "beta": 1.407, "volAvg": 5402177, "mktCap": 19453186018, "lastDiv": 0, "range": "38.81-102.66", "changes": 0.09, "companyName": "Exact Sciences Corporation", "currency": "USD", "cik": "0001124140", "isin": "US30063P1057", "cusip": "30063P105", "exchange": "NASDAQ Capital Market", "exchangeShortName": "NASDAQ", "industry": "Medical - Diagnostics & Research", "website": "https://www.exactsciences.com", "description": "Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.", "ceo": "Kevin T. Conroy", "sector": "Healthcare", "country": "US", "fullTimeEmployees": "6900", "phone": "608 284 5700", "address": "5505 Endeavor Lane", "city": "Madison", "state": "WI", "zip": "53719", "dcfDiff": 132.93814, "dcf": -30.508139330174377, "image": "https://images.financialmodelingprep.com/symbol/EXAS.png", "ipoDate": "2001-02-01", "defaultImage": false, "isEtf": false, "isActivelyTrading": true, "isAdr": false, "isFund": false}]